Drugs / GE180
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03702816 | Dec 2018 → Sep 2019 | Alzheimer disease, Parkinson disease | Aaron Ritter, MD | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GE180 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03702816 ↗ |
| Known as | Flutriciclamide (F18-GE180) | “Flutriciclamide (F18-GE180)” NCT03702816 ↗ |
| Modality | Diagnostic / imaging agent | “used in imaging studies to analyze regional inflammation in living patients” NCT03702816 ↗ |
| Target | TSPO | “binds to TSPO” NCT03702816 ↗ |